Wonder Leaf
Total Consideration
$50.0K
Share price: $0.23
BESPOKE EXTRACTS, INC. — Key Metrics
2 years of history · ending 2024-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-0
Book Value Per Share
$-0
Free Cash Flow Per Share
$-0
Cash Per Share
$0
Revenue Per Share
$0
OCF Per Share
$-0
Return on Equity
54.4%
Return on Assets
-290.8%
Return on Invested Capital
41.2%
Current Ratio
0.15
Quick Ratio
0.12
Asset Turnover
3.13
Days Sales Outstanding
18.71
Days Inventory On Hand
17.87
SBC / Revenue
17.7%
Capex / Revenue
53.7%
Working Capital
$-953K
Net Current Asset Value
$-2M
Invested Capital
$-2M
OCF / Net Income
0.28
FCF / Net Income
0.86
Accruals Ratio (Sloan)
-208.2%
Net Debt
$-7K
Net Debt / EBITDA
0.00
Interest Coverage
-16.56
Cash Coverage
-4.82
Capex Coverage
-0.48
Tangible Common Equity
$-2M
TCE / Total Assets
-582.6%
NOPAT
$-786K
Cash ROIC
46.6%
WC / Revenue
-85.3%
Capex / D&A
62.26
Reinvestment Rate
-59.4%
Total Payout Ratio
—
Asset Growth vs Revenue Growth
-40.9%
Revenue 5Y CAGR
78.2%
Stock Price (FY-end)
$0
Market Cap
$640K
P/E Ratio
—
P/S Ratio
0.57
Enterprise Value
$640K
EV / EBITDA
—
EV / Sales
0.57
FCF Yield
-139.0%
Shareholder Yield
-30.9%
Capex Yield
93.7%
Shares Variation (YoY)
3.5%
Beta (5Y)
0.24
Cost of Equity
5.7%
52W High
$0
52W Low
$0
Trailing Return 1Y
71.3%
Trailing Return 5Y
-84.1%
F-Score (Piotroski)
4.00
Z-Score (Altman)
-112.00
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Stock Price on Earnings Dates
BESPOKE EXTRACTS, INC. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
| Reconciliation Line | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 25.00% | 25.00% | 25.00% | 25.00% | 21.00% | 21.00% |
| State & Local Income Taxes | — | — | — | -25.00% | — | — |
| Foreign Rate Differential | — | — | — | — | — | — |
| Other Adjustments | 20.00% | 22.50% | 0.28% | 0.28% | — | — |
| Valuation Allowance Change | 5.00% | 2.50% | 24.72% | 24.72% | -24.52% | -24.52% |
| Tax Law Change | — | — | — | — | — | — |
| Effective Tax Rate | — | — | — | — | — | — |
Cash vs Accrual
| Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | — | — | — | — | — | — |
| Income Taxes Paid (Cash) | $978.4K | — | −$250.0K | — | — | — |
BESPOKE EXTRACTS, INC. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.